SEOUL, South Korea--(BUSINESS WIRE)--PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx.

韩国首尔--（商业新闻短讯）--PROTEINA今天宣布，它与Janghee Woo教授及其在亚特兰大埃默里大学医学院的研究团队举行了启动会议，开始对其旗舰产品PPI PathFinder BCL2 Dx进行全球临床验证。

PPI PathFinder BCL2 Dx incorporates PROTEINA’s “SPID (Single-molecule Protein Interaction Detection)” technology, enabling high-sensitivity detection of protein-protein interaction (PPI) complexes of BCL2 family proteins and more accurate prediction of any PPI inhibitors targeting the BCL2 family. In this clinical validation, PPI PathFinder BCL2 Dx will be used to predict drug responsiveness in patients with Acute Myeloid Leukemia (AML), providing clinicians with guidance for more effective prescriptions of the widespread BCL2-targeted cancer drug “Venetoclax.”.

PPI PathFinder BCL2 Dx结合了PROTEINA的“SPID（单分子蛋白质相互作用检测）”技术，能够高灵敏度检测BCL2家族蛋白质的蛋白质-蛋白质相互作用（PPI）复合物，并更准确地预测任何针对BCL2家族的PPI抑制剂。在这项临床验证中，PPI PathFinder BCL2 Dx将用于预测急性髓细胞白血病（AML）患者的药物反应性，为临床医生提供指导，以更有效地处方广泛的BCL2靶向抗癌药物“Venetoclax”。

PROTEINA has previously conducted clinical validation of the same product domestically with the Hematologic Cancer Team at Seoul National University, and the findings are scheduled to be soon published in a high-profile scientific journal, Nature Biomedical Engineering, later this year.

PROTEINA之前曾与首尔国立大学血液癌症研究小组在国内对同一产品进行过临床验证，研究结果预计将于今年晚些时候发表在备受瞩目的科学期刊《自然生物医学工程》上。

Starting in May, PROTEINA will transport its Pi-View analysis device and related reagents to labs at Emory. Dr. Janghee Woo, a hematologist at Emory, has spearheaded a translational research laboratory focused on deciphering the molecular mechanisms underlying hematological malignancies to improve clinical outcomes.

从五月开始，PROTEINA将把它的Pi-View分析设备和相关试剂运送到埃默里的实验室。埃默里大学的血液学家Janghee Woo博士领导了一个转化研究实验室，专注于破译血液系统恶性肿瘤的分子机制，以改善临床结果。

This endeavor entails the collection and examination of several hundred AML samples to investigate the molecular intricacies of the disease and pinpoint biomarkers linked to therapeutic response. PROTEINA and Dr. Woo’s research team will analyze these samples using the PPI PathFinder BCL2 Dx to validate its clinical efficacy..

这项工作需要收集和检查数百个AML样本，以研究该疾病的分子复杂性，并确定与治疗反应相关的生物标志物。PROTEINA和Woo博士的研究团队将使用PPI PathFinder BCL2 Dx分析这些样本，以验证其临床疗效。。

Dr. Janghee Woo expressed optimism, stating, “This project will not only validate the clinical efficacy of the PPI PathFinder but also allow for collaboration across various fields through the expansion of solutions to further indications of Venetoclax.”

Janghee Woo博士表示乐观，他说：“这个项目不仅将验证PPI探路者的临床疗效，而且还可以通过扩大解决方案以进一步适应Venetoclax的适应症，在各个领域进行合作。”

PROTEINA’s CEO, Tae-Young Yoon, remarked, “Having successfully completed domestic clinical validation in South Korea over the past two years, we are very excited about this large-scale clinical validation in the United States. We are committed to diligently completing the validation process as this would represent the first step towards wide use of PROTEINA SPID platform in providing PPI biomarkers for the emerging class of PPI-modulating drugs.”.

PROTEINA的首席执行官Tae Young Yoon表示：“过去两年在韩国成功完成了国内临床验证，我们对美国的大规模临床验证感到非常兴奋。我们致力于努力完成验证过程，因为这将是广泛使用PROTEINA SPID平台为新兴类PPI调节药物提供PPI生物标志物的第一步。”。

Furthermore, through this project, PROTEINA aims to enhance the technological competitiveness of PPI PathFinder and the SPID platform and plans to supply the solution to overseas CLIA-certified labs based on the results of this exploratory clinical study.

此外，通过该项目，PROTEINA旨在提高PPI PathFinder和SPID平台的技术竞争力，并计划根据这项探索性临床研究的结果，为海外CLIA认证的实验室提供解决方案。

About PROTEINA

关于PROTEINA

Founded in 2015 in Seoul, PROTEINA is a leader in proteomics, enhancing drug research with its innovative Single-molecule Protein Interaction Detection (SPID) technology. This platform provides exceptional sensitivity for detecting protein-protein interactions, essential for pharmaceutical R&D. Serving top pharmaceutical companies and academic institutions worldwide, PROTEINA’s technology advances understanding of human biology, supporting modern healthcare solutions.

PROTEINA于2015年在首尔成立，是蛋白质组学领域的领导者，凭借其创新的单分子蛋白质相互作用检测（SPID）技术加强了药物研究。该平台为检测蛋白质-蛋白质相互作用提供了异常的灵敏度，这对于药物研发至关重要。PROTEINA的技术为全球顶级制药公司和学术机构服务，促进了对人类生物学的理解，支持了现代医疗保健解决方案。

With collaborations across Europe and North America, PROTEINA delivers insights that propel drug development and proteomic research..

通过在欧洲和北美的合作，PROTEINA提供了推动药物开发和蛋白质组学研究的见解。。